{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:26:16Z","timestamp":1783664776232,"version":"3.55.0"},"reference-count":30,"publisher":"Baishideng Publishing Group Inc.","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"DOI":"10.12998\/wjcc.v10.i28.10085","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T10:59:28Z","timestamp":1664189968000},"page":"10085-10096","source":"Crossref","is-referenced-by-count":3,"title":["One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C"],"prefix":"10.12998","volume":"10","author":[{"given":"Jing-Hang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Wen","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Fang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.35"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31865-8"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.048"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"B7","unstructured":"World Health Organization.   Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva, 2015. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549059"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01711-x"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10262-y"},{"key":"B10","unstructured":"Marcellin P GE, Flisiak R. Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology 2014; 60: 313A-314A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1712-z"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.032"},{"key":"B13","doi-asserted-by":"crossref","unstructured":"Chuang WL AK, Hwang JS, Caruntu F, Wong F, Hann HW, et al Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 wk.   \n            J Hepatol 2017; 66: S695","DOI":"10.1016\/S0168-8278(17)31865-2"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Agarwal K FS, Seto WK, Lim YS, Gane E, Janssen HL, et al A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96.   \n            J Hepatol 2017; 66: S478","DOI":"10.1016\/S0168-8278(17)31347-8"},{"key":"B15","doi-asserted-by":"crossref","unstructured":"Brunetto M LY, Gane E, Seto WK, Osipenko M, Ahn SH, et al A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): efficacy and safety results at week 96.   \n             J Hepatol 2017; 66: S25-S26","DOI":"10.1016\/S0168-8278(17)30313-6"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051287"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0486-8"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02859.x"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23785"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01271.x"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.036"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.45"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13440"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24406"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.04.037"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2003.03318.x"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i28\/10085.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T11:00:16Z","timestamp":1664190016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v10\/i28\/10085.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":30,"journal-issue":{"issue":"28"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v10.i28.10085","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}